Cervical Cancer Screening (NQF 0032)

eMeasure Name Cervical Cancer Screening eMeasure Id 193ED38C-7C8F-43DF-BB18-3EA7B19A23D3
Version number 1 eMeasure Set Id 6910C0F3-5879-4419-ACE0-786C2944C5D3
Available Date No information Measurement Period January 1, 20xx through December 31, 20xx
Measure Steward National Committee for Quality Assurance
Endorsed by National Quality Forum
Description The percentage of women 21-63 years of age who received one or more Pap tests to screen for cervical cancer.
Copyright
© National Committee for Quality Assurance. All Rights Reserved
Measure scoring Proportion
Measure type Process
Stratification
None
Risk Adjustment
None
Data Aggregation
Rationale
American Cancer Society (ACS, Nov 2002):  Test approximately 3 years after onset of vaginal intercourse, but no later than age 21; intervals annually, every 2-3 years for women >=30 with 3 negative cytology tests.

U. S. Preventive Services Task Force (USPSTF, Jan 2003): Test within 3 years of onset of sexual activity or age 21, whichever comes first; intervals of at least every 3 years.

American College of Obstetricians and Gynecologists (ACOG, Aug 2003): Approximately 3 years after onset of sexual intercourse, but no later than age 21; annually, every 2-3 years for women >=30 with 3 negative cytology tests.
Clinical Recommendation Statement
This measure assesses the percentage of women in a specific age demographic who receive appropriate screening for cervical cancer. The American Cancer Society predicted that in 2009, nearly 11,270 women would be newly diagnosed with cervical cancer and 4,070 women would die of cervical cancer. The financial burden is also noteworthy: treatment for cervical cancer cost about $2 billion in 2004 (CDC). The American Cancer Society reported that screening can save lives, stating that the overall five-year survival rate for cervical cancer is nearly 71%, with a survival rate of 92% for detection in the earliest stage (2010). This evidence is corroborated by the fact that from 1955-1992, the mortality rate from cervical cancer declined by 74% because of screening. This measure facilitates efforts toward early detection of cervical cancer and acceleration of treatment upon diagnosis.
Improvement notation
Higher score indicates better quality
Measurement duration
36 month(s)
Reference
USPSTF. Screening for Cervical Cancer. Jan 2003. Available at: http://www.ahcpr.gov/clinic/uspstf/uspscerv.htm
Reference
American Cancer Society. Cancer Facts & Figures 2005. Atlanta: American Cancer Society; 2005.
Definition
Initial Patient Population(s): All female patients 24 to 64 years of age during the measurement period.
Definition
Denominator(s): Patients in the initial population with an encounter during measurement period.
Definition
Denominator Exclusion(s): Female patients who had a hysterectomy with no residual cervix
Definition
Numerator(s): The number of female patients who had one or more Pap tests during the measurement period
Definition
Denominator Exception(s): N/A
Guidance
Note: Given the measurement look back period, women 18 to 64 years of age as of December 31 of the measure period will be captured in this measure.
Supplemental Data Elements
Report "Patient Characteristic: Gender" using "Gender HL7 Value Set (2.16.840.1.113883.1.11.1)"; Report "Patient Characteristic: Race" using "Race CDC Value Set (2.16.840.1.114222.4.11.836)"; Report "Patient Characteristic: Ethnicity" using "Ethnicity CDC Value Set (2.16.840.1.114222.4.11.837)"; Report "Patient Characteristic: Payer" using "Payer Source of Payment Typology Value Set (2.16.840.1.113883.3.221.5)".

Table of Contents


Population criteria

Data criteria (QDM Data Elements)

Supplemental Data Elements




Measure set CLINICAL QUALITY MEASURE SET 2011-2012